China Universal Asset Management Co. Ltd. Cuts Stake in Alnylam Pharmaceuticals, Inc. $ALNY

China Universal Asset Management Co. Ltd. trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 18.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 22,787 shares of the biopharmaceutical company’s stock after selling 5,030 shares during the quarter. Alnylam Pharmaceuticals comprises 0.9% of China Universal Asset Management Co. Ltd.’s portfolio, making the stock its 22nd largest position. China Universal Asset Management Co. Ltd.’s holdings in Alnylam Pharmaceuticals were worth $10,391,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth $25,000. Salomon & Ludwin LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $27,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at about $30,000. ORG Partners LLC increased its stake in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $37,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ALNY shares. Leerink Partners dropped their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research report on Tuesday, January 20th. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price on the stock. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Truist Financial cut their price objective on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $429 and kept a buy rating, signaling meaningful upside versus the current quote. Canaccord price-target raise
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and set a $510 price target (~50% above the current level), providing a bullish benchmark for upside expectations. HC Wainwright note
• Positive Sentiment: Freedom Capital upgraded ALNY from Hold to Strong-Buy, adding to positive analyst momentum. Freedom Capital upgrade
• Positive Sentiment: Large institutional buying reported in Q4 (notable stake increases by Guggenheim, Caisse, Schonfeld and AQR) suggests strong institutional conviction and supports liquidity/demand for the shares.
• Neutral Sentiment: Short-interest entries in the feed show zero/NaN and a 0.0 days-to-cover figure — this looks like a data/reporting artifact rather than new shorting pressure; treat as non-actionable until exchange-confirmed data appears.
• Neutral Sentiment: Analysts collectively trimmed some near-term targets but still express confidence in 2026 growth — mixed model adjustments rather than a broad sell-off. Analysts trim targets
• Negative Sentiment: Several insiders sold shares this week, including CEO Yvonne Greenstreet (~6,958 shares) and multiple senior executives (Kevin Fitzgerald, Pushkal Garg, others). Large, clustered insider sales can weigh on sentiment even if they are routine or pre-planned. CEO sale SEC filing
• Negative Sentiment: Chardan trimmed its price target to $425 (a modest downgrade relative to some peers), and ALNY’s most recent quarterly report showed an EPS miss (Feb. 12) despite strong revenue growth — reminders of execution/near-term margin risk. Chardan target cut

Alnylam Pharmaceuticals Stock Up 2.0%

Shares of Alnylam Pharmaceuticals stock opened at $339.37 on Friday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a market capitalization of $45.01 billion, a PE ratio of 198.46 and a beta of 0.35. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The business has a 50-day moving average of $368.11 and a 200-day moving average of $423.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the prior year, the company posted ($0.65) EPS. The company’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This represents a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 36,578 shares of company stock worth $12,416,105 over the last ninety days. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.